Lonza Announces Agreement with Alexion
The addition of a new manufacturing line at Lonza’s Portsmouth, NH site enables Alexion to add dedicated product supply for 10 years.
Lonza Group announced on July 2 a long-term product supply agreement with Alexion under which Lonza will construct and launch a new suite dedicated to Alexion manufacturing at Lonza’s Portsmouth, NH site. Lonza reports the manufacturing line will be operational by the end of 2017
The agreement, and expansion of an existing manufacturing agreement, will supplement existing production of Alexion products at multiple Lonza facilities. Lonza will own and operate the suite at the Portsmouth site.
The expansion of the existing site will provide increased access to Lonza’s biological manufacturing and regulatory expertise, global workforce and customer service. Lonza has more than two decades of manufacturing experience with mammalian biotherapeutics.
Source: Lonza
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
